Li Yong-Shuang, Zou Ying, Dai Dong-Qiu
Department of Gastrointestinal Surgery, the Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, China.
World J Gastrointest Oncol. 2019 Oct 15;11(10):842-856. doi: 10.4251/wjgo.v11.i10.842.
Ectopic expression of miRNAs promotes tumor development and progression. miRNA (miR)-320a is downregulated in many cancers, including gastric cancer (GC). However, the mechanism underlying its downregulation and the role of miR-320a in GC are unknown.
To determine expression and biological functions of miR-320a in GC and investigate the underlying molecular mechanisms.
Quantitative real-time polymerase chain reaction (PCR) was used to determine expression of miR-320a in GC cell lines and tissues. TargetScanHuman7.1, miRDB, and microRNA.org were used to predict the possible targets of miR-320a, and a dual luciferase assay was used to confirm the findings. Western blotting was used to detect the protein levels of pre-B-cell leukemia homeobox 3 (PBX3) in GC cells and tissue samples. Cell Counting Kit-8 proliferation, Transwell, wound healing, and apoptosis assays were performed to analyze the biological functions of miR-320a in GC cells. Methylation-specific PCR was used to analyze the methylation level of the miR-320a promoter CpG islands. 5-Aza-2'-deoxycytidine (5-Aza-CdR) and trichostatin A (TSA) were used to treat GC cells.
miR-320a expression was lower in GC cell lines and tissues than in the normal gastric mucosa cell line GES-1 and matched adjacent normal tissues. miR-320a overexpression suppressed GC cell proliferation, invasion and migration, and induced apoptosis. PBX3 was a target of miR-320a in GC. The methylation level of the miR-320a promoter CpG islands was elevated and this was partly reversed by 5-Aza-CdR and TSA.
miR-320a acts as a tumor suppressor and inhibits malignant behavior of GC cells, partly by targeting PBX3. DNA methylation is an important mechanism associated with low expression of miR-320a.
微小RNA(miRNA)的异位表达促进肿瘤的发生和发展。miRNA(miR)-320a在包括胃癌(GC)在内的多种癌症中表达下调。然而,其下调的机制以及miR-320a在胃癌中的作用尚不清楚。
确定miR-320a在胃癌中的表达及生物学功能,并探讨其潜在的分子机制。
采用定量实时聚合酶链反应(PCR)检测miR-320a在胃癌细胞系和组织中的表达。利用TargetScanHuman7.1、miRDB和microRNA.org预测miR-320a的潜在靶标,并通过双荧光素酶报告基因检测进行验证。采用蛋白质免疫印迹法检测胃癌细胞和组织样本中前B细胞白血病同源盒3(PBX3)的蛋白水平。通过细胞计数试剂盒-8增殖实验、Transwell实验、伤口愈合实验和凋亡实验分析miR-320a在胃癌细胞中的生物学功能。采用甲基化特异性PCR分析miR-320a启动子CpG岛的甲基化水平。用5-氮杂-2'-脱氧胞苷(5-Aza-CdR)和曲古抑菌素A(TSA)处理胃癌细胞。
miR-320a在胃癌细胞系和组织中的表达低于正常胃黏膜细胞系GES-1及相应的癌旁正常组织。miR-320a过表达抑制胃癌细胞的增殖、侵袭和迁移,并诱导细胞凋亡。PBX3是miR-320a在胃癌中的靶标。miR-320a启动子CpG岛的甲基化水平升高,5-Aza-CdR和TSA可部分逆转这种甲基化。
miR-320a作为一种肿瘤抑制因子,部分通过靶向PBX3抑制胃癌细胞的恶性行为。DNA甲基化是与miR-320a低表达相关的重要机制。